C3 Glomerulopathy in Children: When to Use Anti-Cellular Immunosuppression?
"Navigating treatment options for C3GP, a rare kidney disease in children, and the ongoing debate about anti-cellular immunosuppression."
C3 glomerulopathy (C3GP) is a rare and complex kidney disease where the complement system, part of the immune system, abnormally attacks the kidneys. This leads to damage within the glomeruli, the kidney's filtering units. Diagnosis is confirmed through a kidney biopsy with specific staining techniques.
Managing C3GP is challenging, with varied treatment approaches used by doctors. These range from supportive care to powerful immunosuppressant drugs and targeted therapies like eculizumab. The optimal approach remains a subject of debate.
A new study sheds light on the complexities of C3GP treatment in children, examining the use of anti-cellular immunosuppression, medications that dampen the immune system's activity. By reviewing data from 11 children with C3GP, researchers aimed to contribute to the limited evidence base guiding treatment decisions.
A Rare but Serious Kidney Disease
C3 glomerulopathy is rare, with United States incidence estimates ranging from approximately 1 case per 1,000,000 to 2–3 cases per 1,000,000, based on registry data reporting 49 cases per year over three years. Its prevalence in the United States might be as low as 5 cases per 1,000,000. C3G includes dense deposit disease and C3 glomerulonephritis and frequently leads to end-stage kidney failure, while no specific treatment currently exists.
Defining the Complement-Driven Disorder
C3 glomerulopathy is caused by dysregulation of the alternative pathway of the complement cascade, resulting from genetic variants or acquired humoral factors. Expert consensus adopted the term C3 glomerulopathy in 2013 for a group of rare kidney diseases driven by complement dysregulation. The disease is marked by C3 deposition in the glomerulus and can present with features of both nephritic and nephrotic syndromes.
Understanding C3 Glomerulopathy (C3GP): What the Study Revealed
Researchers at a university medical center retrospectively reviewed 307 kidney biopsies performed on 240 children between January 2004 and July 2018. From this group, 11 children were identified as having C3GP based on specific diagnostic criteria.
- Incidence: C3GP was found in 4.6% of the biopsied children.
- Presentation: All children had protein in their urine (proteinuria), and most also had blood in their urine (hematuria). Some experienced nephrotic syndrome (a condition causing swelling and protein loss) or kidney insufficiency.
- Biopsy Findings: Microscopic examination revealed different patterns of kidney damage, with membranoproliferative glomerulonephritis (MPGN) being the most common.
- Complement Abnormalities: All patients had low levels of C3, a key protein in the complement system.
Clarifying Diagnosis and Complement Biology
Recent reviews describe C3G as an ultra-rare kidney disease caused by deregulation of the alternative pathway of complement. Activation of this pathway can produce C3a- and C5a-mediated inflammation, C3b opsonization, and assembly of the alternative-pathway C3 convertase. Kidney biopsy remains central to diagnosis, with prominent C3 deposition and minimal or absent immunoglobulin deposition supporting the diagnosis.
Uncertain Evidence for Immunosuppression
A retrospective study described the incidence, clinical manifestations, histopathology, follow-up, treatment, and outcomes of C3 glomerulopathy in 11 children. However, complement tests alone should not dictate therapy, because clinical features remain central to management decisions. There are no approved treatments or established standards of care for C3G not associated with monoclonal gammopathy, reflecting the lack of randomized controlled trial data.
Limited Evidence from Related Disease
The regional study from Bahia, Brazil, analyzed 47 renal biopsies from adults with nephrotic syndrome and found a predominance of membranoproliferative glomerulonephritis among the histologic patterns. A separate case report described a 35-year-old patient with steroid-resistant nephrotic syndrome caused by membranoproliferative glomerulonephritis and renal failure. In that individual case, cyclosporin A was associated with remission of nephrotic syndrome and substantial renal-function improvement, allowing withdrawal from hemodialysis, but these data do not establish efficacy for children with C3 glomerulopathy.
Key Takeaways and Future Directions
The study highlights the complexity of C3GP in children and the need for individualized treatment strategies. While anti-cellular immunosuppression can be effective for some, it's not a universal solution. Further research is needed to identify which patients are most likely to benefit from specific therapies and to develop more targeted approaches for managing this challenging condition. A trial of classical immunosuppression before eculizumab is still worth trying.
Persistent Uncertainty in Clinical Management
A practical management review notes that substantial experimental and clinical work has accumulated on C3 glomerulopathy and immunoglobulin-mediated membranoproliferative glomerulonephritis. Despite this progress, uncertainties remain about pathophysiology, classification, clinical course, biomarkers, and the relevance of pathology findings. These unresolved issues complicate decisions about treatment, including the role of anti-cellular immunosuppression.
Toward Biologically Targeted Treatment
C3G has an estimated United States incidence of 1–3 cases per million people. Because it can mimic several other glomerular diseases, diagnosis based only on clinical and laboratory features is challenging and requires a kidney biopsy. Emerging treatment research is shifting attention toward therapies that address alternative-pathway dysregulation, while recent reviews report that C3G and primary immune complex-mediated membranoproliferative glomerulonephritis can lead to kidney failure in up to 50% of patients within 10 years.
Beyond Trial Settings
A real-world observational cohort study evaluated pegcetacoplan in adults and children with C3 glomerulopathy and primary immune complex-mediated membranoproliferative glomerulonephritis treated outside clinical-trial settings. Another report described the first documented real-world use of iptacopan for C3 glomerulopathy in a native kidney. Survey research in Europe and the United States found that patients and families experienced substantial daily burdens, including fatigue and frequent healthcare visits, even though most surveyed patients had stable or improving conditions.